GSK presents phase 3 trial data for Blenrep in r/r multiple myeloma.

GSK “announced results from an interim analysis of the DREAMM-7 phase III head-to-head trial evaluating Blenrep combined with bortezomib plus dexamethasone versus daratumumab plus BorDex in second-line and later treatment of relapsed or refractory multiple myeloma. These data will be presented at the American Society of Clinical Oncology Plenary Series on 6 February 2024. In the primary endpoint of progression-free survival, a statistically significant and clinically meaningful improvement was observed with the belantamab mafodotin combination, showing a 59% reduction in the risk of disease progression or death compared to the daratumumab combination. With a median follow-up of 28.2 months, the median PFS was 36.6 months in the daratumumab combination. The PFS effect was observed across all prespecified subgroups, including those who were refractory to lenalidomide and those with high-risk cytogenetics. The safety and tolerability profile of the belantamab mafodotin combination was consistent with the known profile of the individual agents. The belantamab mafodotin combination also resulted in clinically meaningful improvements in all secondary efficacy endpoints including a doubling of complete response rate (stringent complete response plus complete response), minimal residual disease negativity rate and median duration of response. A strong and clinically meaningful overall survival trend was observed at the interim analysis, with a 43% reduction in the risk of death, which has not yet reached the interim criteria for statistical significance of OS. OS follow-up continues and further analyses are planned.” Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The substantial progression-free survival benefit and strong overall survival trend compared to a daratumumab standard of care combination reinforce our belief in the potential for belantamab mafodotin used in combination to redefine the treatment of multiple myeloma at or after first relapse. We plan on sharing these results with health authorities worldwide.”